Please login to the form below
Bayer promotes Robert LaCaze
He becomes EVP of new oncology strategic business unit
Leverkusen, Germany-based Bayer has promoted Robert LaCaze to executive vice president of its new oncology strategic business unit, part of the firm's pharmaceutical division.
LaCaze joins the pharmaceutical division's executive committee, and will be responsible for implementing the new unit's accelerated development model for new oncology therapies.
He first joined Bayer in 2015 and most recently served as senior vice president and head of global oncology therapeutic area at the firm.
Prior to this, LaCaze spent 27 years at Bristol-Myers Squibb, holding a series of increasingly senior oncology-focused managerial roles, before becoming senior vice president and head of product and portfolio strategy at Bristol-Myers Squibb in 2014.
Dieter Weinand, head of the Bayer Pharmaceutical executive committee, said: “We are delighted to have an executive with Robert LaCaze's experience and talent lead the Oncology Strategic Business Unit.
“I am confident that he will contribute his expertise and foresight to help strengthen our efforts in the fight against cancer.”
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Pfizer reports positive results for elranatamab in multiple myeloma
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer
- Merck sues US government over Medicare drug price negotiation programme
- European Commission grants two new marketing authorisations for UCB's Bimzelx
- AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants
- Janssen shares positive phase 3 results for cilta-cel in multiple myeloma
- Parkinson’s disease: past, present and future
- How to Increase Engagement During Virtual Events
- AstraZeneca to stop post-marketing study of Andexxa following early success
No results were found
PMHub
Medscape Medical Affairs
Medscape Medical Affairs enables all medical affairs professionals to take a more strategic leadership role, and maximize the impact of...
Latest intelligence
- Parkinson’s disease: past, present and future
- Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
